PATH/TOX SYSTEM, the Next Generation is a completely redesigned Toxicology and Pathology data acquisition application designed from the ground up under a full software development lifecycle system
Cedar Knolls, NJ (PRWEB) October 31, 2004 -- Xybion Medical Systems Corporation (Xybion), a developer, and supplier of comprehensive preclinical data management systems announced today that it has released the initial version of its redesigned, industry leading PATH/TOX SYSTEM.
PATH/TOX SYSTEM is a suite of tightly integrated functions that addresses all aspects of preclinical data acquisition, management, and reporting. The current version is in production in nine different countries throughout North America, Europe, and Asia. Clients have the flexibility to license only those functions and options needed to support their study protocols and processes.
Xybion chose to work from the ground up to free itself and its clients from legacy code and associated constraints. Xybions client community has participated as full partners in establishing the functional requirements and user interface for the new system. As a result, the development has produced a system designed by the users for the users. PATH/TOX SYSTEM is the most robust, fully integrated, user-centric, and flexible system on the market.
Xybion also announces a new pricing strategy for PATH/TOX SYSTEM. The new systems pricing is based on the number of licensed named users thereby making it a very affordable choice for any size organization. "PATH/TOX SYSTEM is not only for "Big Pharma" any longer," said David M. Neglia, Xybions Chief Executive Officer, and President. "Our new pricing will enable small pharmaceutical companies, Contract Research Organizations and bio-techs to avail themselves of the worlds best Toxicology and Pathology data acquisition application."
Xybions products are industry leaders and are used by some of the worlds largest and most prestigious pharmaceutical and chemical companies to assess compound safety while reducing time to market.
###
|
